Technical Analysis for RZLT - Rezolute, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 2.64 | 3.13% | 0.08 |
RZLT closed up 3.13 percent on Friday, May 17, 2024, on 78 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
50 DMA Support | Bullish | 3.13% | |
Stochastic Reached Oversold | Weakness | 3.13% | |
Wide Bands | Range Expansion | 3.13% | |
Down 3 Days in a Row | Weakness | 3.13% | |
Down 4 Days in a Row | Weakness | 3.13% | |
Oversold Stochastic | Weakness | 3.13% | |
NR7 | Range Contraction | -0.38% |
Alert | Time |
---|---|
Rose Above Previous Day's High | 2 days ago |
Up 5% | 2 days ago |
60 Minute Opening Range Breakout | 2 days ago |
50 DMA Support | 2 days ago |
Up 3% | 2 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. Its products include RZ358, a human monoclonal antibody that is in Phase II clinical trial for the treatment of congenital hyperinsulinism, a devastating ultra-orphan pediatric disease; and RZ402, a plasma kallikrein inhibitor, which is in late stage preclinical program for the treatment of diabetic macular edema. It also develops AB101, a human recombinant insulin, which is in Phase I clinical trial for the treatment of patients with type 1 and type 2 diabetes mellitus. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Insulin Metabolic Disease Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Diabetes Cancer Treatment Monoclonal Antibody Insulin Metabolic Disease Specialty Drugs Diabetes Mellitus Diabetic Retinopathy Macular Edema Diabetic Macular Edema Kallikrein Plasma Kallikrein
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.69 |
52 Week Low | 0.72 |
Average Volume | 275,225 |
200-Day Moving Average | 1.51 |
50-Day Moving Average | 2.56 |
20-Day Moving Average | 2.86 |
10-Day Moving Average | 2.83 |
Average True Range | 0.29 |
RSI (14) | 46.81 |
ADX | 31.28 |
+DI | 19.94 |
-DI | 17.94 |
Chandelier Exit (Long, 3 ATRs) | 2.82 |
Chandelier Exit (Short, 3 ATRs) | 3.35 |
Upper Bollinger Bands | 3.37 |
Lower Bollinger Band | 2.35 |
Percent B (%b) | 0.29 |
BandWidth | 35.60 |
MACD Line | 0.02 |
MACD Signal Line | 0.09 |
MACD Histogram | -0.073 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.97 | ||||
Resistance 3 (R3) | 2.96 | 2.85 | 2.92 | ||
Resistance 2 (R2) | 2.85 | 2.76 | 2.85 | 2.90 | |
Resistance 1 (R1) | 2.74 | 2.71 | 2.80 | 2.75 | 2.88 |
Pivot Point | 2.63 | 2.63 | 2.65 | 2.63 | 2.63 |
Support 1 (S1) | 2.52 | 2.54 | 2.58 | 2.53 | 2.40 |
Support 2 (S2) | 2.41 | 2.49 | 2.41 | 2.38 | |
Support 3 (S3) | 2.30 | 2.41 | 2.36 | ||
Support 4 (S4) | 2.31 |